BR112013017002A2 - "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas" - Google Patents

"proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"

Info

Publication number
BR112013017002A2
BR112013017002A2 BR112013017002A BR112013017002A BR112013017002A2 BR 112013017002 A2 BR112013017002 A2 BR 112013017002A2 BR 112013017002 A BR112013017002 A BR 112013017002A BR 112013017002 A BR112013017002 A BR 112013017002A BR 112013017002 A2 BR112013017002 A2 BR 112013017002A2
Authority
BR
Brazil
Prior art keywords
unnatural
domain
proteins
mic
target
Prior art date
Application number
BR112013017002A
Other languages
English (en)
Inventor
w martin David
R Williams Steven
Original Assignee
Avidbiotics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidbiotics Corp filed Critical Avidbiotics Corp
Priority claimed from PCT/US2011/042955 external-priority patent/WO2012091756A1/en
Publication of BR112013017002A2 publication Critical patent/BR112013017002A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

proteínas mic não naturais esta invenção descreve moléculas de proteína não naturais, solúveis, monovalentes que podem ativar células nk e certas células t para atacar células de alvo celular especifico, fixando as porções de ligação nkg2d de proteína mica ou micb monovalente, isto é seu domínio de plataforma a1-a2, à célula alvo pretendida especificamente. o domínio a1-a2 é contíguo com um domínio a3 heterólogo que foi geneticamente modificado para se ligar diretamente ou indiretamene ao aspecto extracelular da célula alvo, desse modo servindo como o domínio de alvo. a modifica~ção genética para criar um motivo alvo não natural e não terminal dentro do domínio a3 pode incluir uma porção de um anticorpo, outra molécula de proteína ou porção da mesma, um peptídeo ou um domínio a3 não natural, modificado de uma proteína mic
BR112013017002A 2009-12-31 2011-07-05 "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas" BR112013017002A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29174909P 2009-12-31 2009-12-31
US12/982,827 US8658765B2 (en) 2009-12-31 2010-12-30 Non-natural MIC proteins
PCT/US2011/042955 WO2012091756A1 (en) 2010-12-30 2011-07-05 Non-natural mic proteins

Publications (1)

Publication Number Publication Date
BR112013017002A2 true BR112013017002A2 (pt) 2017-06-06

Family

ID=56291211

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017002A BR112013017002A2 (pt) 2009-12-31 2011-07-05 "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"

Country Status (2)

Country Link
US (1) US8658765B2 (pt)
BR (1) BR112013017002A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091756A1 (en) * 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
CA2823297C (en) * 2010-12-30 2021-05-25 Avidbiotics Corp. Non-natural mic proteins
EP3016973A1 (en) * 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4380604A1 (en) 2021-08-05 2024-06-12 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
WO2024167875A1 (en) 2023-02-07 2024-08-15 Xyphos Biosciences Inc. Chimeric antigen receptor and antibody-nkg2d ligand domain fusion protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
US6821522B2 (en) 2001-05-31 2004-11-23 The Regents Of The University Of California Tumor Therapy
EP1578923A4 (en) * 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES
ATE459374T1 (de) 2003-11-28 2010-03-15 Micromet Ag Polypeptide enthaltende zusammensetzungen
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DE102004042894A1 (de) 2004-08-30 2006-03-02 Eberhard-Karls-Universität Tübingen Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
US20090226466A1 (en) * 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
JP5442998B2 (ja) 2005-12-16 2014-03-19 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 腫瘍性疾患を処置するための手段および方法
JP2010509257A (ja) 2006-11-14 2010-03-25 ゲオルグ−アウグスト−ウニヴェルズテート ゲッティンゲン シュティフトゥング オッフェントリヒェン レヒツ 免疫療法のための組成物および方法
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) * 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins

Also Published As

Publication number Publication date
US8658765B2 (en) 2014-02-25
US20110183893A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
BR112013017002A2 (pt) "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"
BRPI0612273B8 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2674567T3 (es) Proteínas de fusión biespecíficas
RS54340B1 (en) ACE2 POLYPEPTID
IN2012DN02981A (pt)
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
ATE556728T1 (de) Gewebeaufbaugerüste mit homingfaktoren
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
AR062030A1 (es) Proteinas de fusion de exendina
WO2010043650A3 (en) Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry
TN2009000194A1 (en) Novel antiproliferation antibodies
ATE398672T1 (de) Immortalisierte vogelzellinien zur virusproduktion
SG170749A1 (en) Anti-ilt7 antibody
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
NZ595792A (en) Antibodies specific to cadherin-17
AR071672A1 (es) Procedimiento para prevenir el desarrollo de artritis reumatoide en sujetos con artritis indiferenciada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: XYPHOS BIOSCIENCES INC. (US)

B25G Requested change of headquarter approved

Owner name: XYPHOS BIOSCIENCES INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL